NCT06496815View on ClinicalTrials.gov

Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

August 1, 2026

Study Completion Date

July 30, 2027

Conditions
Unresectable Hepatocellular Carcinoma
Interventions
DRUG

Donafenib

Donafenib will be taken orally twice a day, 0.2g each time.

PROCEDURE

transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy

Eligible subjects will receive transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy as previous (if have).

DRUG

PD-1,PD-L1

PD-1/PD-L1 will be used as previous (if have).

All Listed Sponsors
lead

Tongji Hospital

OTHER

NCT06496815 - Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy | Biotech Hunter | Biotech Hunter